Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17


1. Flegal KM, Carrp MD, Kuczmarski RJ, et al.: Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obesity 1998, 22:39–37.

2. Vanitallie TB: Body weight, morbidity and longevity. In Obesity. Edited by Bjorntorp P, Brodoff BN. Philadelphia: JB Lippincott; 1992.

3. Smith SR: Regional fat distribution. In Nutrition, Genetics and Obesity. Edited by Bray GA, Ryan DH. Baton Rouge, LA: Louisiana State University Press; 1999:433–458.

4. Goodpaster B,Thaete F, Somoneau J, et al.: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997, 46:1579–1585.

5. Masuzaki H, Paterson J, Shinyama H, et al.: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294:2071–2072.

6. Ravussin E, Lillioja S, Anderson TE, et al.: Determinants of 24-h energy expenditure in man. J Clin Invest 1986, 778:1568–1578.

7. Prentice AM, Black AE, Coward WA, et al.: High levels of energy expenditure in obese women. Br Med J 1986, 292:983–987.

8. Flatt JP: Importance of nutrient balance in body weight regulation. Diabetes Metab Rev 1988, 4:571–581.

9. Flatt JP, Gupte S: In Nutrition, Genetics and Obesity. Edited by Bray GA, Ryan DH. Baton Rouge, LA: Louisiana State University Press; 1999:73–88.

10. Anand BK, Brobeck JR: Hypothalamic control of food intake in rates and cats. Yale J Biol Med 1951, 24:123.

11. Hetherington A, Ranson SW: Hypothalamic lesions and adiposity in the rat. Anat Rec 1940, 78:149.

12. Qu D, Ludwig DS, Gammeltoft S, et al.: A role for melanin concentrating hormone in the central regulation of feeding behavior. Nature 1996, 380:243–246.

13. Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:1–696.

14. Wellman PJ: Norepinephrine and the control of food intake. Nutrition 2000, 16:837–842.

15. Tsujii S, Bray GA:A beta-3 adrenergic agonist (BRL-37,344) decreases food intake. Physiol Behav 1998, 63:723–728.

16. Yamashita J, Onai T,York DA, Bray GA: Relationship between food intake and metabolic rate in rats treated with beta-adrenoceptor agonists. Int J Obes Relat Metab Disord 1994, 18:429–433.

17. Yang ZJ, Meguid MM, Chai JK, et al.: Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size. Pharmacol Biochem Behav 1997, 58:631–635.

18. Pothos EN, Creese I, Hoebel BG: Restricted eating with weight loss selectively decreases extracellular dopamine in the nucleus accumbens and alters dopamine response to amphetamine, morphine and food intake. J Neurosci 1995, 15:6640–6650.

19. Turton MD, Oshea D, Bloom SR: Central effects of neuropeptide Y with emphasis on its role in obesity and diabetes. In Neuropeptide Y and Drug Development. Edited by Grundemar L, Bloom SR. San Diego:Academic Press; 1997:15–39.

20. Stanley BG, Kyrkouli SE, Lampert S, et al.: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7:1189–1192.

21. Billington CJ, Briggs JE, Grace M, et al.: Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991, 260(2 Pt 2):R321–R327.

22. Halford JC, Blundell JE: Pharmacology of appetite suppression. Prog Drug Res 2000, 54:25–58.

23. Horvath TL, Diano S, Sotonyi P, et al.: Minireview: ghrelin and the regulation of energy balance—a hypothalamic perspective. Endocrinology 2001, 142:4163-9.

24. Hansen TK, Dall R, Hosoda H, et al.: Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol 2002, 56:203–206.

25. Hagan MM: Peptide YY: a key mediator of orexigenic behavior. Peptides 2002, 23:377–382.

26. Naslund E, Barkeling B, King N, et al.: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999, 23:304–311.

27. Degen L, Matzinger D, Drewe J, Beglinger C:The effect of cholecys-tokinin in controlling appetite and food intake in humans. Peptides 2001, 22:1265–1269.

28. Woods SC, Seeley RJ: Adiposity signals and the control of energy homeostasis. Int J Obes Relat Metab Disord 2001, 25(Suppl 5):S35–S38.

29. Zhang Y, Proenca R, Maffei M, et al.: Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372:425–432.

30. Halaas JL, Gajiwala KS, Maffei M, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543–546.

31. Ahima RS, Prabakaran D, Mantzoros C, et al.: Role of leptin in the neuroendocrine response to fasting. Nature 1996, 383:250–252.

32. Shimada M,Tritos NA, Lowell BB, et al.: Mice lacking melanin concentrating hormone are hypophagic and lean. Nature 1998, 396:670–674.

33. Ericson JC, Clegg KE, Palmiter RD: Sensitivity to leptin and susceptibility to seizures in mice lacking neuropeptide Y. Nature 1996, 381:415–418.

34. Erickson JC, Hollopeter G, Palmiter RD:Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274:1704–1707.

35. Tartaglia LA, Dembski M,Weng X, et al.: Identification and expression cloning of a leptin receptor, OB-R. Cell 1995, 83:1263–1271.

36. Elias CF, Saper CB, Maratos-Flier E, et al.: Chemically defined projection linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998, 402:442–459.

37. Mountjoy KG, Robbinsa LS, Mortrud MT, et al.: The cloning of a family of genes that encode the melanocortin receptors. Science 1992, 257:1248–1251.

38. Montague CT, Farooqi IS,Whitehead JP, et al.: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387:903–908.

39. Clement K,Vaisse C, Lahlou N, et al.: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998, 392:398–401.

40. Tsujii S, Bray GA:Acetylation alters the feeding response to MSH and beta-endorphin. Brain Res Bull 1989, 23:165–169.

41. Yen TT, Gill AM, Frigeri LG, et al.: Obesity, diabetes and neoplasia in the yellow Avy/- mice: ectopic expression of the agouti gene. FASEB J 1994, 8:481–488.

42. Blanchard SG, Harris CO, Ittoop OR, et al.: Agouti antagonism of melanocortin binding and action in the B16F10 murine melanoma cell line. Biochemistry 1995, 34:10406–10411.

43. Lu D, Willard D, Patel IR, et al.: Agouti protein is an antagonist of the melanocyte-stimulating hormone receptor. Nature 1994, 371:799–802.

44. Huszar D, Lynch CA, Fairchild-Huntress V, et al.: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131–141.

45. Shutter JR, Graham M, Kinsey AC, et al.: Hypothalamic expression ART, a novel gene related to agouti, is up-regulated in obese and mutant mice. Genes Dev 1997, 11:593–602.

46. Ollmann MM,Wilson BD,Yang YK, et al.: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 281:135–138.

47. Yeo GS, Farooqi IS, Aminian S, et al.: A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998, 20:111–112.

48. Vaisse C, Clement K, Guy-Grand B, et al.: A frameshift mutation human MC4R is associated with a dominant form of obesity. Nat 1998, 20:113–114.

49. Krude H, Biebermann H, Luck W, et al.: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998, 9:155–157.

50. Jackson RS, Creemers JW, Ohagi S, et al.: Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997, 16:303–306.

51. Ristow M, Muller-Wieland D, Pfeiffer A, et al.: Obesity associated mutation in a genetic regulator of adipocyte differentiation. N Engl 1998, 339:953–959.

52. The practical guide: identification, evaluation, and treatment of over-weight and obesity in adults. Bethesda, MD: National Heart, Lung, Blood Institute, North American Association for the Study of Obesity, 2000. (NIH publication n.00-4048.) Available at http://www.nhlbi.nih.gov/guidelines/obesity/practgde.htm.Accessed 7, 2002.

53. Bray GA, Blackburn GL, Ferguson JM, et al.: Sibutramine produces dose-related weight loss. Obes Res 1999, 7:189–198.

54. Hauptman J, Guerciolini R, Nichols G: Orlistat: a novel treatment obesity. In Nutrition, Genetics and Obesity. Edited by Bray GA, Ryan Baton Rouge, LA: Louisiana State University Press; 1998.

55. Yanovski SZ,Yanovski JA: Obesity. N Engl J Med 2002, 346(8):591–602

56. Mun EC, Blackburn GL, Matthews JB: Current status of medical surgical therapy for obesity. Gastroenterology 2001, 120:669–681.

 voltar